Floatz logo

Vibecotamab

Chronic Myeloid Leukemia, Blast Crisis

Xencor, Inc.monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

43 Active assets in the Chronic Myeloid Leukemia, Blast Crisis cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Imatinib
The University of Hong Kong
Phase 2BB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB
Nilotinib
The University of Hong Kong
Phase 2BB

View all 50 →

Same molecule, other indications

Vibecotamab is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
53 / 100
View asset →
CD4+/CD56+ hematodermic neoplasmDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →